Histogenics' NeoCart Autologous Cartilage Tissue Implant may be a better treatment than microfracture for cartilage repair, according to a company news release.
According to the Phase 2 data for NeoCart ACTI, which was presented at the American Orthopaedic Society for Sports Medicine Annual Meeting, patients with knee cartilage injury who were treated with NeoCart reported better outcomes at the six and 12 month follow-ups than patients who underwent microfracture.
NeoCart is a bio-engineered neo-cartilage implant containing autologous chondrocyte population matured in a biodegradable collagen matrix.
Read the report on NeoCart.
Related Articles on Cartilage Repair:
Dr. Brian Cole: Developing the Future of Cartilage Regeneration in Orthopedics
U.S. Cartilage Repair Market to Grow 6.8% Over Next 4 Years
Northwestern Researchers Develop Nanofiber Gel That May Promote Growth of New Cartilage
NeoCart is a bio-engineered neo-cartilage implant containing autologous chondrocyte population matured in a biodegradable collagen matrix.
Read the report on NeoCart.
Related Articles on Cartilage Repair:
Dr. Brian Cole: Developing the Future of Cartilage Regeneration in Orthopedics
U.S. Cartilage Repair Market to Grow 6.8% Over Next 4 Years
Northwestern Researchers Develop Nanofiber Gel That May Promote Growth of New Cartilage